KYTX (Kyverna Therapeutics) Long-Term Capital Lease Obligation : $3.35 Mil (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Long-Term Capital Lease Obligation?

Kyverna Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was $3.35 Mil.

Kyverna Therapeutics's quarterly Long-Term Capital Lease Obligation declined from Sep. 2024 ($5.21 Mil) to Dec. 2024 ($4.30 Mil) and declined from Dec. 2024 ($4.30 Mil) to Mar. 2025 ($3.35 Mil).

Kyverna Therapeutics's annual Long-Term Capital Lease Obligation declined from Dec. 2022 ($8.29 Mil) to Dec. 2023 ($6.16 Mil) and declined from Dec. 2023 ($6.16 Mil) to Dec. 2024 ($4.30 Mil).

Kyverna Therapeutics Long-Term Capital Lease Obligation Historical Data

The historical data trend for Kyverna Therapeutics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Long-Term Capital Lease Obligation Chart

Kyverna Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Long-Term Capital Lease Obligation

4.74

8.29

6.16

4.30

Kyverna Therapeutics Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial						7.13	6.13	5.21	4.30	3.35

Kyverna Therapeutics (NAS:KYTX) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Kyverna Therapeutics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyverna Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

5980 Horton Street, Suite 550, Emeryville, CA, USA, 94608

Website

https://www.kyvernatx.com

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.